Hunan Yinzhe Huahao Biotechnology

Hunan Yinzhe Huahao Biotechnology is a Chinese biopharmaceutical company focused on the discovery and development of innovative small molecule drugs for oncology and immunology. The company is a strategic joint venture between Yinzhe (Shanghai) Biotechnology and Hunan Huahao Pharmaceutical, combining cutting-edge R&D with regional industrialization expertise. Its core research platform centers on DNA Damage Response (DDR) and synthetic lethality, aiming to develop therapies for cancers with specific genetic mutations. The lead candidate, YZ-101, is a selective USP1 inhibitor currently in Phase 1 clinical trials for advanced solid tumors. By targeting the ubiquitin-proteasome system, the company seeks to overcome resistance to existing PARP inhibitors and other standard treatments. Based in Changsha, Hunan Yinzhe Huahao is positioned to advance a pipeline of precision medicines from early discovery through clinical proof-of-concept.